The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis

Journal of Neurochemistry

Volumn 77, Issue 4, 2001, Pages 1116-1127

  Chen, Nianhang ^a,b   Vaughan, Roxanne A ^c   Reith, Maarten E A ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Binding; Cocaine analogue; Dopamine transporter; Mutagenesis; Uptake

Indexed keywords

ASPARTIC ACID; CHLORIDE ION; COCAINE; DOPAMINE TRANSPORTER; SODIUM ION; TRYPTOPHAN;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ASPARTIC ACID; CARRIER PROTEINS; CELL LINE; COCAINE; CONSERVED SEQUENCE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; KINETICS; MAZINDOL; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; NERVE TISSUE PROTEINS; PROTEIN STRUCTURE, SECONDARY; RADIOLIGAND ASSAY; RECOMBINANT PROTEINS; TRANSFECTION; TRITIUM; TRYPTOPHAN;

EID: 0035020831     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00312.x     Document Type: Article

References (41)

1. Amara S. G. and Sonders M. S. (1998) Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 51, 87-96.
2. Barker E. L., Moore K. R., Rakhshan F. and Blakely R. D. (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J. Neurosci. 19, 4705-4717.
3. Bennett J. P. Jr (1978) Methods in binding studies, in Neurotransmitter Receptor Binding (Yamamura H. I., Enna S. J. and Kuhar M. J., eds), pp. 57-90. Raven Press, New York.
4. -)-coupled GABA transporter from rat brain, impairs net flux but not exchange. J. Biol. Chem. 275, 34106-34113.
5. Chen N. and Justice J. B. J. (1998) Cocaine acts as an apparent competitive inhibitor at the outward-facing conformation of the human norepinephrine transporter: kinetic analysis of inward and outward transport [in process citation]. J. Neurosci. 18, 10257-10268.
6. Chen N. and Justice J. B. (2000) Differential effect of structural modification of human dopamine transporter on the inward and outward transport of dopamine. Brain Res. Mol. 75, 208-215.
7. Chen N. and Reith M. E. A. (2000) Structure and function of the dopamine transporter. Eur J. Pharmacol. 405, 329-339.
8. Chen N., Ferrer J. V., Javitch J. A. and Justice J. B. Jr (2000) Transport-dependent accessibility of a cytoplasmic loop cysteine in the human dopamine transporter. J. Biol. Chem. 275, 1608-1614.
9. 50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
10. Daniels G. M. and Amara S. G. (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 274, 35794-35801.
11. Dougherty D. A. (1996) Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science 271, 163-168.
12. Ferrer J. V. and Javitch J. A. (1998) Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc. Natl Acad. Sci. USA 95, 9238-9243.
13. Fersht A. (1985). Enzyme Structure and Mechanism, pp. 98-120. W.H. Freeman, New York.
14. Galli A., Blakely R. D. and DeFelice L. J. (1998) Patch-clamp and amperometric recordings from norepinephrine transporters: channel activity and voltage-dependent uptake [see comments]. Proc. Natl Acad. Sci. USA 95, 13260-13265.
15. Gallivan J. P. and Dougherty D. A. (1999) Cation-π interactions in structural biology. Proc. Natl Acad. Sci. USA 96, 9459-9464.
16. Giros B., Jaber M., Jones S. R., Wightman R. M. and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
17. Keshet G. I., Bendahan A., Su H., Mager S., Lester H. A. and Kanner B. I. (1995) Glutamate-101 is critical for the function of the sodium and chloride-coupled GABA transporter GAT-1. FEBS Lett. 371, 39-42.
18. Kitayama S., Shimada S., Xu H., Markham L., Donovan D. M. and Uhl G. R. (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl Acad. Sci. USA 89, 7782-7785.
19. Lanyi J. K. (1997) Mechanism of ion transport across membranes. Bacteriorhodopsin as a prototype for proton pumps. J. Biol. Chem. 272, 31209-31212.
20. Lee F. J., Pristupa Z. B., Ciliax B. J., Levey A. I. and Niznik H. B. (1996) The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain. J. Biol. Chem. 271, 20885-20894.
21. Lin Z., Wang W., Kopajtic T., Revay R. S. and Uhl G. R. (1999) Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol. Pharmacol. 56, 434-447.
22. Lin Z., Wang W. and Uhl G. R. (2000) Dopamine transporter tryptophan mutants highlight candidate dopamine-and cocaine-selective domains. Mol. Pharmacol. 58, 1581-1592.
23. Martin S., Botto J. M., Vincent J. P. and Mazella J. (1999) Pivotal role of an aspartate residue in sodium sensitivity and coupling to G proteins of neurotensin receptors. Mol. Pharmacol. 55, 210-215.
24. Masson J., Sagné C., Hamon M. and el Mestikawy S. (1999) Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51, 439-464.
25. Melikian H. E., Ramamoorthy S., Tate C. G. and Blakely R. D. (1996) Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol. Pharmacol. 50, 266-276.
26. Nguyen T. T. and Amara S. G. (1996) N-Linked oligosaccharides are required for cell surface expression of the norepinephrine transporter but do not influence substrate or inhibitor recognition. J. Neurochem. 67, 645-655.
27. Opdenakker G., Rudd P. M., Ponting C. P. and Dwek R. A. (1993) Concepts and principles of glycobiology. FASEB J. 7, 1330-1337.
28. Poolman B., Knol J., van der Does C., Henderson P. J., Liang W. J., Leblanc G., Pourcher T. and Mus-Veteau I. (1996) Cation and sugar selectivity determinants in a novel family of transport proteins. Mol. Microbiol. 19, 911-922.
29. Rees S., Coote J., Stables J., Goodson S., Harris S. and Lee M. G. (1996) Bicistronic vector for the creation of stable mammaliam cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 20, 102-110.
30. Reith M. E. A. (2000) From first to fourth messengers in the brain: an overview, in Cerebral Signal Transduction (Reith M. E. A., ed.), pp. 3-23. Humana Press, Totowa, NJ.
31. Reith M. E., Xu C., Zhang L. and Coffey L. L. (1996) Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter. Naunyn Schmiedebergs Arch. Pharmacol. 354, 295-304.
32. Rudnick G. (1997) Mechanisms of biogenic amine neurotransmitter transporters, in: Neurotransmitter Transporters: Structure, Function, and Regulation (Reith M. E. A., ed.), pp. 73-100. Humana Press, Totowa, NJ.
33. Schömig E., Körber M. and Bönisch H. (1988) Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier. Naunyn Schmiedebergs Arch. Pharmacol. 337, 626-632.
34. Stein M. D. (1986). Transport and Diffusion Across Cell Membranes, pp. 231-361. Academic Press,Orlando, FL.
35. Steiner-Mordoch S., Shirvan A. and Schuldiner S. (1996) Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate. J. Biol. Chem. 271, 13048-13054.
36. Sugamori K. S., Lee F. J., Pristupa Z. B. and Niznik H. B. (1999) A cognate dopamine transporter-like activity endogenously expressed in a COS-7 kidney-derived cell line. FEBS Lett. 451, 169-174.
37. Vaughan R. A. (1995) Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol. Pharmacol. 47, 956-964.
38. Vaughan R. A. (2000) Regulation of dopamine transporter by phosphorylation and impact on cocaine action, in: Cerebral Signal Transduction (Reith M. E. A., ed.), pp. 375-400. Humana Press, Totowa, NJ.
39. Vaughan R. A. and Kuhar M. J. (1996) Dopamine transporter ligand binding domains. Structural and functional properties revealed by limited proteolysis. J. Biol. Chem. 271, 21672-21680.
40. Xu C. and Reith M. E. (1997) WIN 35,428 and mazindol are mutually exclusive in binding to the cloned human dopamine transporter. J. Pharmacol. Exp. Ther. 282, 920-927.
41. Zimányi I., Lajtha A. and Reith M. E. A. (1989) Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Naunyn Schmiedebergs Arch. Pharmacol. 340, 626-632.